Universal Children’s Day

Today, November 20th, is Universal Children’s Day. This year,  we are celebrating in Cape Town, South Africa, where the EPIICAL 3rd General Assembly is being hosted. Universal Children’s Day is dedicated to the rights of the child, with one key aspect being the right for every child to access the highest standard of health. However, at the end of 2018, there were 37.9 million people living with HIV worldwide and, among them, 1.7 million are children aged less the 15 years. Continue reading “Universal Children’s Day”

EPIICAL publication on Journal of AIDS: treat early, suppress fast!

Treat early, suppress fast!

In a new paper just published online in Journal of AIDS, EPIICAL researchers investigated the association between the timing of antiretroviral therapy (ART) initiation and time-to suppression​ among HIV-infected infants who initiated​ ART within the first 28 days of life. Continue reading “EPIICAL publication on Journal of AIDS: treat early, suppress fast!”

EARTH study – first patient enrolled in Mali

We are delighted to report that the Centre Hospitalier Universitaire Gabriel Touré in Mali (in liaison with Anne-Genevieve Marcelin, France) has enrolled its first patient in the key EPIICAL study, EARTH. This marks a new chapter in the study, with the scope of the cohort widening to include participants not only from South Africa and Mozambique, but also from the west African site in Bamako. Continue reading “EARTH study – first patient enrolled in Mali”


With issue of the 2nd EPIICAL newsletter, we are pleased to announce that a poster on the CARMA study has been accepted for a presentation at both the 10th International AIDS Society 2019 Conference on HIV Science and pre-meeting ‘2019 HIV & HBV Cure Forum‘.

Pablo Rojo, on behalf of the CARMA study researchers, will illustrate the main factors associated with low viral reservoir in a large multi-centre cohort of early treated children infected with HIV on sustained suppressive ART for more than a decade. Globally, the CARMA study is the focal point of EPIICAL investigations and will provide important insights into clinical and biological features of early treated suppressed HIV-infected children, as well as novel strategies to achieve long-term viral suppression without ART in this particular population.

The biannual IAS Conference on HIV Science is the world’s most influential meeting on HIV research and its applications. Gathering more than 5,000 participants from over 140 countries, IAS 2019 will present the most critical advances in basic, clinical and operational HIV research that moves science into policy and practice.

Read more here!